tiprankstipranks
Advertisement
Advertisement

MLYS Stock Latest News

Mineralys Shareholders Approve Directors and Auditor at Meeting
Company AnnouncementsMineralys Shareholders Approve Directors and Auditor at Meeting
4d ago
8K
MLYS
Mineralys: Buy Rating Reiterated on Superior Lorundrostat Profile vs. Baxfendy and Unchanged $42 Price Target
PremiumRatings
Mineralys: Buy Rating Reiterated on Superior Lorundrostat Profile vs. Baxfendy and Unchanged $42 Price Target
7d ago
MLYS
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
PremiumThe Fly
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
8d ago
AZN
MLYS
Mineralys Therapeutics Maps Path After Lorundrostat NDA
PremiumCompany Announcements
Mineralys Therapeutics Maps Path After Lorundrostat NDA
19d ago
MLYS
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
PremiumThe Fly
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
19d ago
MLYS
Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
PremiumThe FlyMineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
20d ago
MLYS
Mineralys Therapeutics initiated with a Buy at TD Cowen
Premium
The Fly
Mineralys Therapeutics initiated with a Buy at TD Cowen
29d ago
MLYS
Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
Premium
The Fly
Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
2M ago
IMUX
MLYS
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer
PremiumThe Fly
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer
2M ago
MLYS
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
PremiumRatings
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
2M ago
MLYS
Mineralys Therapeutics Charts Path After NDA Acceptance
PremiumCompany Announcements
Mineralys Therapeutics Charts Path After NDA Acceptance
2M ago
MLYS
Mineralys Therapeutics price target raised to $51 from $46 at BofA
PremiumThe Fly
Mineralys Therapeutics price target raised to $51 from $46 at BofA
2M ago
MLYS
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
PremiumThe FlyMineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
2M ago
MLYS
Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings
Premium
The Fly
Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings
2M ago
MLYS
MLYS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
MLYS Upcoming Earnings Report: What to Expect?
3M ago
MLYS
Mineralys Reports Mixed Phase 2 Results for Lorundrostat
PremiumCompany Announcements
Mineralys Reports Mixed Phase 2 Results for Lorundrostat
3M ago
8K
MLYS
Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA
PremiumThe Fly
Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA
3M ago
MLYS
Mineralys Therapeutics Inc options imply 20.5% move in share price post-earnings
PremiumThe Fly
Mineralys Therapeutics Inc options imply 20.5% move in share price post-earnings
3M ago
MLYS
Mineralys Therapeutics Inc options imply 16.5% move in share price post-earnings
PremiumThe Fly
Mineralys Therapeutics Inc options imply 16.5% move in share price post-earnings
3M ago
MLYS
Mineralys Therapeutics Inc options imply 21.7% move in share price post-earnings
PremiumThe FlyMineralys Therapeutics Inc options imply 21.7% move in share price post-earnings
3M ago
MLYS
Mineralys Therapeutics Inc options imply 13.2% move in share price post-earnings
Premium
The Fly
Mineralys Therapeutics Inc options imply 13.2% move in share price post-earnings
3M ago
MLYS
Mineralys Therapeutics Inc call volume above normal and directionally bullish
Premium
The Fly
Mineralys Therapeutics Inc call volume above normal and directionally bullish
4M ago
MLYS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >